Please try another search
For the three months ended 31 March 2022, Samjin Pharmaceutical Co., Ltd. revenues increased 10% to W60.8B. Net income decreased 47% to W3.63B. Revenues reflect Injection segment increase of 61% to W8.45B, Other Products segment increase of 14% to W7.79B, Foreign Country segment increase of 16% to W1.06B. Net income was offset by Advertising Expense increase of 45% to W2.86B (expense), Scientific Expense increase of 30% to W1.74B (expense).
Period Ending: | Dec 31, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
---|---|---|---|---|
Total Revenue | 60802.65 | 48529.1 | 81965.22 | |
Gross Profit | 25966.47 | 18915.02 | 42145.85 | |
Operating Income | 5093.34 | -3970.73 | 20384.65 | |
Net Income | 3628.02 | -2419.77 | 15820.91 |
Period Ending: | Dec 31, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
---|---|---|---|---|
Total Assets | 406556.94 | 355330.66 | 332495.96 | 325342.58 |
Total Liabilities | 130692.79 | 127376.88 | 98327.95 | 90904.68 |
Total Equity | 275864.15 | 227953.78 | 234168.02 | 234437.91 |
Period Ending: | Dec 31, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 |
---|---|---|---|---|
Period Length: | 0 Months | 3 Months | 0 Months | 9 Months |
Cash From Operating Activities | 10282.59 | 23967.39 | 19294.54 | |
Cash From Investing Activities | -18452.24 | -71555.3 | -41231 | |
Cash From Financing Activities | 19668.54 | 36619.15 | 20858.96 | |
Net Change in Cash | 11498.89 | -10968.76 | -1077.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review